Expert Interview
Discussing DVAX' HEPLISAV-B vaccine and market potential post approval
Ticker(s): DVAX, GSKAn infectious disease expert with experience treating patients that have HEP-B, as well as vaccinating people with GSK's Engerix-B
Can you give us an idea of the Hep-B vaccine market now, what types of patients get vaccinated and how well covered people are currently?
Added By: c_adminPlease give us a little information about your background in Hep-B.
Added By: c_adminWhat is your impression to the Phase 3 data released by Dynavax?
Added By: c_adminWhat is the current standard of care for high risk populations, like diabetics, elderly and obese patients? How do you see HEPLISAV-B changing this paradigm?
Added By: c_adminIs Bells Palsy a side effect associated with current adult hepatitis B vaccines (Engerix)? How would a two dose regimen over 4 weeks impact compliance versus a three dose regimen over 6 months in the typical target patient in your opinion?
Added By: c_adminWhat can you tell us about compliance among diabetics since ACIP's recommendation re: hep b vaccination four years ago? If low, is this an education issue? Compliance issue? Other?
Added By: c_adminDo you see the data for HEPLISAV-B being compelling enough that you would switch from using Engerix-B to HBV-23 if it was approved?
Added By: c_adminHow much would a two dose regimen over one month improve compliance vs. the three dose regimen over 6 months in your opinion?
Added By: c_adminHow would you view a premium price for HEPLISAV-B, considering the potential compliance improvements?
Added By: c_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
